Real-time Estimate
Cboe BZX
12:26:37 2024-06-27 EDT
|
5-day change
|
1st Jan Change
|
0.291
USD
|
-0.31%
|
|
+15.04%
|
-87.81%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
229.4
|
179.8
|
74.5
|
158.8
|
152
|
18.82
|
-
|
-
|
Enterprise Value (EV)
1 |
229.4
|
179.8
|
74.5
|
158.8
|
152
|
18.82
|
18.82
|
18.82
|
P/E ratio
|
-3.95
x
|
-3.36
x
|
-1.17
x
|
-3.4
x
|
-4.07
x
|
-0.56
x
|
-0.65
x
|
-0.56
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
17.7
x
|
64.2
x
|
2,118
x
|
15,197
x
|
-
|
7.04
x
|
19.8
x
|
EV / Revenue
|
-
|
17.7
x
|
64.2
x
|
2,118
x
|
15,197
x
|
-
|
7.04
x
|
19.8
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-4.4
x
|
-4.57
x
|
-1.3
x
|
-3.41
x
|
-
|
-0.46
x
|
-0.44
x
|
-0.32
x
|
FCF Yield
|
-22.7%
|
-21.9%
|
-77.2%
|
-29.3%
|
-
|
-218%
|
-226%
|
-314%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
43,360
|
47,829
|
51,739
|
52,424
|
64,393
|
64,464
|
-
|
-
|
Reference price
2 |
5.290
|
3.760
|
1.440
|
3.030
|
2.360
|
0.2919
|
0.2919
|
0.2919
|
Announcement Date
|
2/28/20
|
3/2/21
|
3/3/22
|
3/29/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
10.16
|
1.16
|
0.075
|
0.01
|
-
|
2.672
|
0.95
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-61.39
|
-51.51
|
-63.45
|
-47.4
|
-39.28
|
-35.22
|
-40.72
|
-45.44
|
Operating Margin
|
-
|
-506.83%
|
-5,469.57%
|
-63,204%
|
-392,750%
|
-
|
-1,523.84%
|
-4,783.08%
|
Earnings before Tax (EBT)
1 |
-57.89
|
-51.03
|
-63.43
|
-46.69
|
-36.9
|
-33.65
|
-48.4
|
-56.41
|
Net income
1 |
-57.89
|
-51.03
|
-63.43
|
-46.69
|
-36.9
|
-34.19
|
-40.51
|
-45.46
|
Net margin
|
-
|
-502.09%
|
-5,467.84%
|
-62,250.67%
|
-368,990%
|
-
|
-1,515.64%
|
-4,785%
|
EPS
2 |
-1.340
|
-1.120
|
-1.230
|
-0.8900
|
-0.5800
|
-0.5250
|
-0.4500
|
-0.5175
|
Free Cash Flow
1 |
-52.13
|
-39.31
|
-57.5
|
-46.54
|
-
|
-41
|
-42.5
|
-59
|
FCF margin
|
-
|
-386.8%
|
-4,957.28%
|
-62,055.57%
|
-
|
-
|
-1,590.27%
|
-6,210.53%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/28/20
|
3/2/21
|
3/3/22
|
3/29/23
|
3/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
0.018
|
-
|
0.075
|
-
|
-
|
-
|
-
|
-
|
0.01
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-17.43
|
-14.66
|
-13.35
|
-8.768
|
-10.62
|
-10.94
|
-8.93
|
-9.814
|
-9.591
|
-11.12
|
-9.684
|
-7.928
|
-6.486
|
-10.7
|
-12.7
|
Operating Margin
|
-96,811.11%
|
-
|
-17,804%
|
-
|
-
|
-
|
-
|
-
|
-95,910%
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-17.42
|
-14.65
|
-13.27
|
-8.524
|
-10.24
|
-10.36
|
-8.259
|
-9.203
|
-9.079
|
-10.74
|
-9.43
|
-7.43
|
-6.05
|
-10.7
|
-12.7
|
Net income
1 |
-17.42
|
-14.65
|
-13.27
|
-8.524
|
-10.24
|
-10.36
|
-8.259
|
-9.203
|
-9.079
|
-10.74
|
-9.448
|
-7.756
|
-6.248
|
-10.7
|
-12.7
|
Net margin
|
-96,788.89%
|
-
|
-17,689.33%
|
-
|
-
|
-
|
-
|
-
|
-90,790%
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.3300
|
-0.2800
|
-0.2500
|
-0.1600
|
-0.1900
|
-0.1700
|
-0.1300
|
-0.1400
|
-0.1400
|
-0.1700
|
-0.1500
|
-0.1200
|
-0.0950
|
-0.1500
|
-0.2000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/3/22
|
4/28/22
|
8/3/22
|
11/9/22
|
3/29/23
|
5/3/23
|
8/2/23
|
11/3/23
|
3/27/24
|
5/9/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-52.1
|
-39.3
|
-57.5
|
-46.5
|
-
|
-41
|
-42.5
|
-59
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.14
|
0.07
|
0.01
|
0.08
|
-
|
0.05
|
1.54
|
2.55
|
Capex / Sales
|
-
|
0.67%
|
1.29%
|
112.25%
|
-
|
-
|
57.44%
|
267.89%
|
Announcement Date
|
2/28/20
|
3/2/21
|
3/3/22
|
3/29/23
|
3/27/24
|
-
|
-
|
-
|
Last Close Price
0.2919
USD Average target price
0.75
USD Spread / Average Target +156.94% Consensus |
1st Jan change
|
Capi.
|
---|
| -87.81% | 18.82M | | +16.81% | 122B | | +19.99% | 115B | | +21.22% | 26.64B | | -23.23% | 19.91B | | -17.47% | 16.32B | | -45.95% | 15.52B | | -18.71% | 15.49B | | +60.83% | 14.83B | | +3.42% | 13.67B |
Bio Therapeutic Drugs
|